Compass Pathways Successfully Achieves Primary Endpoint In First Phase 3 Trial

Compass Pathways PLC CMPS:

• COMPASS PATHWAYS SUCCESSFULLY ACHIEVES PRIMARY ENDPOINT IN FIRST PHASE 3 TRIAL EVALUATING COMP360 PSILOCYBIN FOR TREATMENT-RESISTANT DEPRESSION

• COMPASS PATHWAYS PLC - COMP360 SHOWS SIGNIFICANT REDUCTION IN SYMPTOM SEVERITY IN PHASE 3 TRIAL

• COMPASS PATHWAYS PLC - DSMB FINDS NO UNEXPECTED SAFETY ISSUES WITH COMP360

• COMPASS PATHWAYS PLC - COMP006 TRIAL 26-WEEK DATA EXPECTED IN SECOND HALF OF 2026